Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers

Checkpoint inhibitors represent the first therapeutic class to replace chemotherapy lines for the treatment of metastatic non-small cell lung cancer (NSCLC), due to improved overall survival and tolerability. Nivolumab, a fully human anti-programmed cell death-1 immunoglobulin G4 monoclonal antibody...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Ther Med
Main Authors: Săftescu, Sorin, Negru, Șerban, Volovăț, Simona, Popovici, Dorel, Chercota, Vlad, Stanca, Simona, Feier, Horea, Malita, Daniel, Dragomir, Radu, Volovăț, Constantin
Formato: Artigo
Idioma:Inglês
Publicado em: D.A. Spandidos 2021
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8082661/
https://ncbi.nlm.nih.gov/pubmed/33936262
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2021.10037
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados